芪苈强心胶囊对柔红霉素心脏毒性预防和治疗作用研究  

Preventive and Therapeutic Effect of Qili Qiangxin Capsule on Daunorubicin Cardiotoxicity

作　　者：李晓辉[1] 王亚君[1] 张国利[1] 张剑白[1] 

机构地区：[1]哈尔滨医科大学附属第一医院,黑龙江哈尔滨150001

出　　处：《辽宁中医药大学学报》2017年第6期27-30,共4页Journal of Liaoning University of Traditional Chinese Medicine

基　　金：黑龙江省中医药科研课题项目(ZHY12-Z147)

摘　　要：目的:探讨芪苈强心胶囊对柔红霉素所致心脏毒性的预防和治疗作用。方法:选择8~10周龄健康雄性SD大鼠48只随机分为4组各12只,对照组(等量生理盐水处理)、柔红霉素组(柔红霉素2 mg/kg)、芪苈强心组(芪苈强心胶囊生药1 g/kg,以0.9%氯化钠溶液溶为2 g/mL悬浊液灌胃)、柔红霉素+芪苈强心组(柔红霉素2.0 mg/kg+芪苈强心胶囊生药1 g/kg,以0.9%氯化钠溶液溶为2 g/mL悬浊液灌胃)。结果:柔红霉素组的AST、ALT、LDH、α-HBDH、CK、CKMB水平均显著高于对照组、芪苈强心组(P<0.05);柔红霉素+芪苈强心组的AST、ALT、LDH、α-HBDH、CK、CKMB水平均显著的高于对照组、芪苈强心组(P<0.05),柔红霉素+芪苈强心组的AST、ALT、LDH、α-HBDH、CK、CKMB水平均显著低于柔红霉素组(P<0.05);柔红霉素组、柔红霉素+芪苈强心组的TSOD及GSH-Px活性水平、LVEF值均显著低于对照组、芪苈强心组(P<0.05),MDA含量、LVEDD值显著的高于对照组、芪苈强心组(P<0.05);柔红霉素+芪苈强心组的TSOD及GSH-Px活性水平、LVEF值均显著的高于柔红霉素组(P<0.05),MDA含量、LVEDD值显著的低于柔红霉素组(P<0.05)。结论:芪苈强心胶囊对柔红霉素所致心脏毒性具有预防和治疗作用,作用机制可能与发挥其增强心功能、减轻心肌细胞的过氧化损伤有关。Objective： To investigate the preventive and therapeutic effect of Qili Qiangxin Capsule on daunorubicin induced cardiotoxicity. Methods ： 48 rats were randomly divided into four groups of 12 rats each 8-10 weeks old healthy male SD rats, control group （ physiological saline ）, daunorubicin group （ daunorubicin 2.0 mg/kg ）, Qili Qiangxin group （ Qili Qiangxin Capsule drug 1 g/kg, with 0.9% sodium chloride solution solution for 2 g/mL suspension turbid liquid intragastrically ）, soft erythromycin＋ Qili Qiangxin group （ daunorubicin 2.0 mg/kg＋ Qili Qiangxin Capsule drug 1 g/kg, with 0.9% sodium chloride solution solution was 2 g/mL suspension gavage ）. Results ： Daunorubicin group AST, ALT, LDH, α -HBDH, CK, CKMB were significantly higher than of control group and Qili Qiangxin group （ P〈0.05 ）; daunorubicin＋ Qili Qiangxin group AST, ALT, LDH, α-HBDH, CK, CKMB levels were significantly higher in Qili Qiangxin group （ P〈0.05 ）, AST daunorubicin ＋ Qili Qiangxin group, ALT, LDH, α-HBDH, CK, CKMB were significantly lower than daunorubicin group （ P〈0.05 ）; daunorubicin group TSOD and GSH-Px activity levels, LVEF values were significantly lower than the control group and Qili Qiangxin group （ P〈0.05 ）, MDA content, LVEDD value were significantly higher than control group and Qili Qiangxin group （ P〈0.05 ）; daunorubicin group TSOD and GSH-Px activity levels, LVEF values were significantly higher than daunorubicin group （ P〈0.05 ）, MDA content, LVEDD value was significantly lower than daunorubicin group （ P〈0.05 ）. Conclusion ： Qili Qiangxin Capsule has prevention and treatment effect on daunorubicininduced cardiotoxicity, the mechanism may relate with enhancing cardiac function and reducing myocardial cell peroxidation injury.

关 键 词：芪苈强心胶囊 柔红霉素 心脏毒性 

分 类 号：R283[医药卫生—中药学]